Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0KWKQC)
| ADC Name |
DX126-262
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
DX126-262; DAC-001; DX-126-262
Click to Show/Hide
|
|||||
| Organization |
Hangzhou DAC Biotechnology (DAC Biotech) (Originator)
|
|||||
| Drug Status |
Phase 2
|
|||||
| Drug-to-Antibody Ratio |
3.5~3.8
|
|||||
| Structure |
|
|||||
| Antibody Name |
DX-CHO9
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
Tub114
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mal-PEG10 based linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Special Approval(s) |
Special approval (NMPA)
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||||
|---|---|---|---|---|---|---|---|---|
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
|||||||
| Gastric cancer |
1 Trials
|
1 Trials
|
||||||
| Lung cancer |
1 Trials
|
|||||||
| Breast cancer |
1 Trials
|
1 Trials
|
||||||
| Urothelial cancer |
1 Trials
|